Page 236 - Read Online

Gabriele et al. J Cancer Metastasis Treat 2018;4:17 I http://dx.doi.org/10.20517/2394-4722.2018.06 Page 17 of 17

123. Long J, Zhao J, Yan Z, Liu Z, Wang N. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40.
Int J Cancer 2009;124:1235-44.
124. Patra N, De U, Kim TH, Lee YJ, Ahn MY, Kim ND, Yoon JH, Choi WS, Moon HR, Lee BM, Kim HS. A novel histone deacetylase
(HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Biomed Pharmacother 2013;67:407-15.
125. Beaver LM, Yu TW, Sokolowski EI, Williams DE, Dashwood RH, Ho E. 3,3’-Diindolylmethane, but not indole-3-carbinol, inhibits
histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol 2012;236:345-51.
126. Choi ES, Han G, Park SK, Lee K, Kim HJ, Cho SD, Kim HM. A248, a novel synthetic HDAC inhibitor, induces apoptosis through the
inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells. Mol Med Rep 2013;8:195-200.
127. Vallo S, Mani J, Stastny M, Makarević J, Juengel E, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA. The prostate cancer blocking
potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Invest
New Drugs 2013;31:265-72.
128. Hoang JJ, Baron S, Volle DH, Lobaccaro JM, Trousson A. Lipids, LXRs and prostate cancer: are HDACs a new link? Biochem
Pharmacol 2013;86:168-74.
129. Tang X, Jia J, Li F, Liu W, Yang C, Jin B, Shi Q, Wang X, He D, Guo P. Salen-Mn compounds induces cell apoptosis in human prostate
cancer cells through promoting AMPK activity and cell autophagy. Oncotarget 2017;8:86277-86.